Neuphoria Therapeutics (NEUP) Payables (2020 - 2026)
Neuphoria Therapeutics (NEUP) reported Payables of $627185.0 for Q1 2026, down 15.85% year-over-year from $745336.0 in Q1 2025, and up 20.45% quarter-over-quarter from $520709.0 in Q4 2025.
Neuphoria Therapeutics (NEUP) Payables (2020 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has 7 years of Payables data on file, last reported at $627185.0 in Q1 2026.
- Payables for Q1 2026 came in at $627185.0, down 15.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $627185.0 (down 15.85% YoY), and the FY2025 annual result was $1.2 million, down 48.55% from the prior year.
- Payables improved to $627185.0 in Q1 2026 per NEUP's latest filing, from $520709.0 in the prior quarter.
- Over five years, Payables peaked at $2.2 million in Q2 2024 and troughed at $520709.0 in Q4 2025.
- A 5-year average of $1.3 million and a median of $1.3 million in 2024 frame the typical range for Payables.
- The sharpest annual moves came in 2022 and 2025: Payables surged 151.93% in 2022, then tumbled 65.98% in 2025.
- A 5-year view of Payables shows it stood at $2.0 million in 2022, then sank by 30.93% to $1.4 million in 2023, then grew by 11.04% to $1.5 million in 2024, then plunged by 65.98% to $520709.0 in 2025, then climbed by 20.45% to $627185.0 in 2026.
- Business Quant data shows NEUP's Payables at $627185.0 in Q1 2026, $520709.0 in Q4 2025, and $1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 1.05 Mn |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 300,549.00 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 83.00 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 8.69 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 489.30 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 34.55 Mn |
| 10 | Neuphoria Therapeutics | 23.86 Mn | 4.46 Mn | - | 627,185.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 627,185.00 |
| Dec 31, 2025 | 520,709.00 |
| Sep 30, 2025 | 1.37 Mn |
| Jun 30, 2025 | 1.15 Mn |
| Mar 31, 2025 | 745,336.00 |
| Dec 31, 2024 | 1.53 Mn |
| Sep 30, 2024 | 1.33 Mn |
| Jun 30, 2024 | 2.24 Mn |
| Jun 30, 2023 | 1.38 Mn |
| Jun 30, 2022 | 2.00 Mn |
| Jun 30, 2021 | 792,189.61 |
| Jun 30, 2020 | 1.52 Mn |